Cancer Gene Therapy

Key patent obtained for p53 targeted chemotherapy

Published in Gene Therapy Weekly, November 14th, 2002

Introgen Therapeutics, Inc., (INGN) and the University of Texas M.D. Anderson Cancer Center announced that the U.S. Patent and Trademark Office has issued to the Board of Regents of the University of Texas System U.S. Patent No. 6,410,029 entitled "2-Methoxyestradiol- induced apoptosis in cancer cells."

2-Methoxyestradiol (2ME2) is a potent anticancer agent and angiogenesis inhibitor and also rapidly and efficiently induces p53-mediated apoptosis, or programmed cell death.

The issued patent relates to the treatment of cancer by increasing expression of wild-type p53 in a cancer cell and inducing apoptosis with the introduction of 2ME2. It...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry